Methotrexate Injection, Solution
NDC Package 55150-511-10
Package Information
Methotrexate injection is methotrexate is used to treat certain types of cancer or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. This formulation utilizes a injection, solution delivery system. Marketed by Eugia Us Llc, this product is identified by NDC 55150-511 and is authorized under FDA application ANDA201529.
Identification & Billing
- RxCUI: 1655959 - methotrexate 250 MG in 10 ML Injection
- RxCUI: 1655959 - 10 ML methotrexate 25 MG/ML Injection
- RxCUI: 1655959 - methotrexate 250 MG per 10 ML Injection
- RxCUI: 1655960 - methotrexate 50 MG in 2 ML Injection
- RxCUI: 1655960 - 2 ML methotrexate 25 MG/ML Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intrathecal - Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 55150 - Eugia Us Llc
- 55150-511 - Methotrexate
- 55150-511-10 - 10 VIAL, SINGLE-DOSE in 1 CARTON / 4 mL in 1 VIAL, SINGLE-DOSE
- 55150-511 - Methotrexate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (55150-511). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55150-511-10 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 4 ml in 1 vial, single-dose of Methotrexate, a human prescription drug labeled by Eugia Us Llc. This injection, solution is formulated for intramuscular; intrathecal; intravenous; subcutaneous use and contains methotrexate sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eugia Us Llc on September 11, 2024. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Methotrexate is used to treat certain types of cancer or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.
How is this Eugia Us Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55150051110. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
